Allarity Therapeutics, Inc. engages in the development of drugs for personalized treatment of cancer guided by its proprietary Drug Response Predictor (DRP) technology. The company operates in two geographic areas: Denmark and the United States. The company was founded on April 4, 2021 and is headquartered in Boston, MA.
相关临床试验
9
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
1
11.1%
已完成
3
33.3%
招募中
2
22.2%
终止
3
33.3%
暂无批准数据
- Allarity Therapeutics has opened enrollment for a Phase 2 trial combining stenoparib with temozolomide for recurrent small cell lung cancer patients. - The trial is fully funded by the U.S. Department of Veterans Affairs and is now enrolling at 11 VA sites across the United States. - Stenoparib's dual PARP/tankyrase inhibition mechanism and favorable safety profile may overcome toxicity limitations seen with first-generation PARP inhibitors. - The combination targets both DNA repair pathways and WNT signaling, potentially offering enhanced anti-tumor activity for patients with limited treatment options.
- CHOSA Oncology announced positive results from its collaboration with ETOP/EORTC, demonstrating that the Platin-DRP® biomarker successfully predicted treatment outcomes in advanced non-small cell lung cancer patients. - The 205-gene predictor showed statistically significant prediction of progression-free survival for cisplatin and overall survival for carboplatin in the SPLENDOUR trial analysis. - Additional validation data presented at ESMO 2025 confirmed the predictor's ability to identify metastatic breast cancer patients likely to benefit from carboplatin therapy. - These findings represent important steps toward regulatory approval and integration into treatment guidelines for platinum-based chemotherapy selection across multiple cancer types.
- Allarity Therapeutics received FDA Fast Track designation for stenoparib, an investigational dual PARP/WNT inhibitor for advanced ovarian cancer treatment. - The designation accelerates development timelines and enables more frequent FDA interactions with potential eligibility for expedited approval pathways. - The company has initiated a Phase 2 clinical trial building on prior data showing patients remaining on treatment for over 22 months. - ALLR stock surged over 119% intraday following the regulatory milestone, with trading volume increasing by 2,728% to $304.8 million.
• Allarity Therapeutics has developed a new Drug Response Predictor (DRP®) for daratumumab that can identify multiple myeloma patients most likely to benefit from treatment, as presented at AACR 2025. • The daratumumab DRP® is based on 53 genes associated with treatment sensitivity or resistance, and has demonstrated ability to predict treatment outcomes and survival in clinical samples. • This marks Allarity's first DRP® for an antibody therapy, expanding beyond small-molecule drugs and positioning the company for potential strategic partnerships in precision oncology.
- Allarity Therapeutics is expanding its Phase 2 clinical trial of stenoparib for advanced ovarian cancer, aiming to optimize dosing and patient selection. - The trial focuses on patients with platinum-resistant disease who have shown durable clinical benefit from stenoparib in earlier phases. - Enrollment for the expanded Phase 2 trial is set to begin in the first half of 2025 at leading U.S. trial sites, with potential UK sites. - Stenoparib's impact on the Wnt pathway will be evaluated, potentially differentiating it in the PARP inhibitor market.
- Allarity Therapeutics reports that two patients with advanced ovarian cancer have remained on stenoparib treatment for over 14 months in a Phase 2 trial. - The company's strong financial position, with $18.5 million in cash, supports the advancement of stenoparib towards potential FDA registration. - Allarity's medical laboratory has expanded its services to external biotech clients, generating revenue through gene expression and diagnostic capabilities. - Stenoparib's unique mechanism of action, inhibiting PARP1/2 and tankyrase 1/2, continues to show potential in heavily pretreated ovarian cancer patients.
